Stocks of Evolus Inc. (NASDAQ:EOLS) traded higher last session on Wall Street, down -0.41% to $7.24.
According to the data, Evolus Inc. (NASDAQ:EOLS) has 8 analysts covering its stock. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $25.00 and a low of $10.00, we find $20.00. Given the previous closing price of $7.27, this indicates a potential upside of 175.1 percent. EOLS stock price is now -16.78% away from the 50-day moving average and -14.76% away from the 200-day moving average. The market capitalization of the company currently stands at $418.40M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
A total of 1 analysts have issued a hold rating and 7 have given it a buy rating. Brokers who have rated the stock have averaged $18.88 as their price target over the next twelve months.
With the price target of $18, Needham recently initiated with Buy rating for Evolus Inc. (NASDAQ: EOLS).
In other news, MOATAZEDI DAVID, insider sold 6,110 shares of the company’s stock on Mar 27. The stock was sold for $51,752 at an average price of $8.47. Upon completion of the transaction, the insider now directly owns 609,567 shares in the company, valued at $4.41 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 14, MOATAZEDI DAVID sold 64,211 shares of the business’s stock. A total of $543,797 was realized by selling the stock at an average price of $8.47. This leaves the insider owning 615,677 shares of the company worth $4.46 million. Insiders disposed of 4,363,933 shares of company stock worth roughly $31.59 million over the past 1 year. A total of 13.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in EOLS stock. A new stake in Evolus Inc. shares was purchased by MONASHEE INVESTMENT MANAGEMENT LLC during the first quarter worth $2,063,000. RICE HALL JAMES & ASSOCIATES, LLC invested $1,163,000 in shares of EOLS during the first quarter. In the first quarter, TRI LOCUM PARTNERS LP acquired a new stake in Evolus Inc. valued at approximately $1,160,000. TREXQUANT INVESTMENT LP acquired a new stake in EOLS for approximately $819,000. MARSHALL WACE, LLP purchased a new stake in EOLS valued at around $803,000 in the second quarter. In total, there are 168 active investors with 49.30% ownership of the company’s stock.
Monday’s opening bell rang with an opening price of $7.28 for Evolus Inc. (NASDAQ: EOLS). During the past 12 months, Evolus Inc. has had a low of $6.51 and a high of $14.29. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 2.10, and a quick ratio of 1.50. The fifty day moving average price for EOLS is $8.70 and a two-hundred day moving average price translates $8.49 for the stock.
The latest earnings results from Evolus Inc. (NASDAQ: EOLS) was released for Mar, 2023. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at -$0.15, inline with analysts’ expectations of -$0.15. This compares to -$0.31 EPS in the same period last year. The net profit margin was -45.80% and return on equity was -282.50% for EOLS. The company reported revenue of $41.72 million for the quarter, compared to $33.91 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 23.04 percent. For the current quarter, analysts expect EOLS to generate $47.32M in revenue.
